SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

The use of SGLT2 inhibitors vs sulfonylurea was associated with a reduced risk for incident gout and MACE among patients with type 2 diabetes with/at risk for gout.

In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor ... evolve after the discontinuation of the trial drug. In the active trial, patients with chronic ...

a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Patients also took a single-agent renin-angiotensin system (RAS) inhibitor as background medication. During the combined active- and post-trial ...

Merck and Pfizer are to take on the crowded SGLT2 ... day at list price. The US approval has achieved, the companies await similar clearance in Europe, the other leading market for the drugs.

Anti-Obesity Drugs Show Whole-Body Promise and More Is ... Stages 4 and 5 In a first renal outcome trial of its kind, the SGLT2 inhibitor showed favorable outcomes in the most advanced stages ...